These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

95 related articles for article (PubMed ID: 32638216)

  • 1. Correction to: L-Aspartate, L-Ornithine and L-Ornithine-L-Aspartate (LOLA) and Their Impact on Brain Energy Metabolism.
    Das A; Fröhlich D; Achanta LB; Rowlands BD; Housley GD; Klugmann M; Rae CD
    Neurochem Res; 2020 Oct; 45(10):2527. PubMed ID: 32638216
    [TBL] [Abstract][Full Text] [Related]  

  • 2. L-Aspartate, L-Ornithine and L-Ornithine-L-Aspartate (LOLA) and Their Impact on Brain Energy Metabolism.
    Das A; Fröhlich D; Achanta LB; Rowlands BD; Housley GD; Klugmann M; Rae CD
    Neurochem Res; 2020 Jun; 45(6):1438-1450. PubMed ID: 32424601
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Physiological functions of L-ornithine and L-aspartate in the body and the efficacy of administration of L-ornithine-L-aspartate in conditions of relative deficiency].
    Sikorska H; Cianciara J; Wiercińska-Drapało A
    Pol Merkur Lekarski; 2010 Jun; 28(168):490-5. PubMed ID: 20642112
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Effect of L-ornithine L-aspartate granules in treating chronic liver disease in patients with high-level serum gamma-glutamyltransferase].
    Yan Z; Wang Y; Mao Q; Wang X; Zhang X; Wang Y; Jiang Y; Xiang DD; Jiang L; Wang J
    Zhonghua Gan Zang Bing Za Zhi; 2014 Jul; 22(7):525-8. PubMed ID: 25203805
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Hepatoprotection by L-Ornithine L-Aspartate in Non-Alcoholic Fatty Liver Disease.
    Butterworth RF; Canbay A
    Dig Dis; 2019; 37(1):63-68. PubMed ID: 30016770
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pharmacokinetic and Pharmacodynamic Properties of L-Ornithine L-Aspartate (LOLA) in Hepatic Encephalopathy.
    Kircheis G; Lüth S
    Drugs; 2019 Feb; 79(Suppl 1):23-29. PubMed ID: 30706424
    [TBL] [Abstract][Full Text] [Related]  

  • 7. L-ornithine vs. L-ornithine-L-aspartate as a treatment for hyperammonemia-induced encephalopathy in rats.
    Vogels BA; Karlsen OT; Mass MA; Boveé WM; Chamuleau RA
    J Hepatol; 1997 Jan; 26(1):174-82. PubMed ID: 9148009
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A double-blind, randomized, placebo-controlled trial of intravenous L-ornithine-L-aspartate on postural control in patients with cirrhosis.
    Schmid M; Peck-Radosavljevic M; König F; Mittermaier C; Gangl A; Ferenci P
    Liver Int; 2010 Apr; 30(4):574-82. PubMed ID: 20456040
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Efficacy of L-ornithine-L-aspartate as an adjuvant therapy in cirrhotic patients with hepatic encephalopathy.
    Abid S; Jafri W; Mumtaz K; Islam M; Abbas Z; Shah HA; Hamid S
    J Coll Physicians Surg Pak; 2011 Nov; 21(11):666-71. PubMed ID: 22078345
    [TBL] [Abstract][Full Text] [Related]  

  • 10. l-ornithine-l-aspartate for hepatic encephalopathy in patients with cirrhosis: a meta-analysis of randomized controlled trials.
    Bai M; Yang Z; Qi X; Fan D; Han G
    J Gastroenterol Hepatol; 2013 May; 28(5):783-92. PubMed ID: 23425108
    [TBL] [Abstract][Full Text] [Related]  

  • 11. L-Ornithine L-Aspartate (LOLA) for Hepatic Encephalopathy in Cirrhosis: Results of Randomized Controlled Trials and Meta-Analyses.
    Butterworth RF; McPhail MJW
    Drugs; 2019 Feb; 79(Suppl 1):31-37. PubMed ID: 30706425
    [TBL] [Abstract][Full Text] [Related]  

  • 12. L-Ornithine-l-aspartate in the management of hepatic encephalopathy: a meta-analysis.
    Jiang Q; Jiang XH; Zheng MH; Chen YP
    J Gastroenterol Hepatol; 2009 Jan; 24(1):9-14. PubMed ID: 18823442
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Efficacy of oral L-ornithine-L-aspartate in cirrhotic patients with hyperammonemic hepatic encephalopathy. Results of a randomized, lactulose-controlled study.
    Poo JL; Góngora J; Sánchez-Avila F; Aguilar-Castillo S; García-Ramos G; Fernández-Zertuche M; Rodríguez-Fragoso L; Uribe M
    Ann Hepatol; 2006; 5(4):281-8. PubMed ID: 17151582
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Randomised clinical trial: L-ornithine-L-aspartate reduces significantly the increase of venous ammonia concentration after TIPSS.
    Bai M; He C; Yin Z; Niu J; Wang Z; Qi X; Liu L; Yang Z; Guo W; Tie J; Bai W; Xia J; Cai H; Wang J; Wu K; Fan D; Han G
    Aliment Pharmacol Ther; 2014 Jul; 40(1):63-71. PubMed ID: 24832463
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Reduction of hospital stay with the use of L-ornithine L-aspartate (LOLA) in patients with hepatic encephalopathy].
    Abdo-Francis JM; Pérez-Hernández JL; Hinojosa-Ruiz A; Hernández-Vásquez JR
    Rev Gastroenterol Mex; 2010; 75(2):135-41. PubMed ID: 20615780
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effect of L-ornithine-L-aspartate on patients with and without TIPS undergoing glutamine challenge: a double blind, placebo controlled trial.
    Rees CJ; Oppong K; Al Mardini H; Hudson M; Record CO
    Gut; 2000 Oct; 47(4):571-4. PubMed ID: 10986219
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Efficacy of L-ornithine L-aspartate in acute liver failure: a double-blind, randomized, placebo-controlled study.
    Acharya SK; Bhatia V; Sreenivas V; Khanal S; Panda SK
    Gastroenterology; 2009 Jun; 136(7):2159-68. PubMed ID: 19505424
    [TBL] [Abstract][Full Text] [Related]  

  • 18. L-Ornithine L-Aspartate (LOLA) as a Novel Approach for Therapy of Non-alcoholic Fatty Liver Disease.
    Canbay A; Sowa JP
    Drugs; 2019 Feb; 79(Suppl 1):39-44. PubMed ID: 30706422
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Glutamate, glutamine, aspartate, asparagine, glucose and ketone-body metabolism in chick intestinal brush-border cells.
    Porteous JW
    Biochem J; 1980 Jun; 188(3):619-32. PubMed ID: 7470024
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Possibilities of therapeutic correction of hyperammonemia and minimal hepatic encephalopathy in patients with chronic hepatitis C at the pre-cirrhotic stage.
    Buyeverov AO; Bogomolov PO; Mayev IV; Matsievich MV; Uvarova OV
    Ter Arkh; 2019 Mar; 91(2):52-58. PubMed ID: 31094172
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.